Article · 30 Dec 2024
Conference abstract
Preliminary results of continuation maintenance treatment with pemetrexed in advanced nonsquamous non-small cell lung cancer (NSCLC) patients after prior induction chemotherapy– singlearm phase II study
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Lung cancer remains one of the leading causes of cancer-related death worldwide. Extending the duration of treatment with the initial platinum based chemotherapy beyond four to six cycles has been evaluated. The aim of this study is to investigate efficacy and toxicity of continuation maintenance treatment with pemetrexed (Alimta) in patients displaying disease control after four cycles of induction with cisplatin plus pemetrexed in advanced non-squamous (NSCLC). Methodology & Theoretical Orientation: Between April 2013 and April 2015, 16 patients with pathologically proven stage III/IV, non-squamous NSCLC, in Clinical Oncology Department, Tanta University Hospital and Tanta Insurance Hospital who had received prior four cycles of induction with cisplatin (75 mg/m2) plus pemetrexed (500 mg/m2) every 21 days without disease progression were enrolled. Patients received continuation maintenance treatment with pemetrexed (500 mg/m2, every 21 days). The primary endpoints of the study were the overall survival and progression-free survival and the secondary end point was the safety profile. Finding: A total of 64 chemotherapy cycles of continuation maintenance pemetrexed were administered. Patients were treated with a median number of 4 cycles (range 2-30 cycles). Two patients received no more than 2 cycles due to rapid disease progression. The estimated median PFS and OS were 7.5 and 17 months, respectively. Treatment-related adverse events were manageable with only 1 patient (6.25%) suffered from Grade 3 anemia and another 1 patient (6.25%) suffered from Grade 4 neutropenia. All patients received full doses of pemetrexed throughout the study. There was no treatment-related death. Conclusion & Significance: Using the continuation maintenance regimen with pemetrexed preceded by four cycles of induction with cisplatin plus pemetrexed represents an obvious treatment advance with an acceptable clinical profile for patients with non-squamous NSCLC.
Keywords
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Epigenetics.
Article · 30 Dec 2024
Nutritional Factors Affecting Epigenetic Regulation in ICU Patients
Article · 30 Dec 2024
Epigenetic Changes in Hypoxia in Critically Ill Patients
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Epigenetics
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Nesreen Mohamed Sabry Afifi Mattar”